AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8594942 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (2 pmol.kg‐1.min‐1 for 2 h)
Number of subjects: 8
Study 2242369 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of salbutamol orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Number of subjects: 60
Study 2242369 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally 30 min before vaginal administration of 2 mg prostaglandin E2 gel
Number of subjects: 60
Study 2242369 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of salbutamol
Number of subjects: 60
Study 2242369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 643495 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred serial practice
Number of subjects: 44
Study 643495 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-preferred serial practice
Number of subjects: 44
Study 643495 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred sequence practice
Number of subjects: 44
Study 643495 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-preferred sequence practice
Number of subjects: 44
Study 643495 — intervention group
Group type: COMPARATOR
Intervention: Order of practice
Number of subjects: 44
Study 27128107 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Simplist (BDS)
Number of subjects: 24
Study 27128107 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpuject (CJ)
Number of subjects: 24
Study 27128107 — intervention group
Group type: COMPARATOR
Intervention: Traditional vial-and-syringe process (TVSP)
Number of subjects: 24
Study 29034598 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-window technique without membrane coverage (Test Group)
Number of subjects: 20
Study 29034598 — intervention group
Group type: COMPARATOR
Intervention: Solo-window technique with membrane coverage (Control Group)
Number of subjects: 20
Study 25041807 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbinate-septal suture plus nasal packing (group B)
Number of subjects: 120
Study 25041807 — intervention group
Group type: COMPARATOR
Intervention: Nasal (group A)
Number of subjects: 120
Study 23588193 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (AT)
Number of subjects: 39
Study 23588193 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 39
Study 23588193 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON(CH))
Number of subjects: 39
Study 20584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability shoe
Number of subjects: 81
Study 20584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion control shoe
Number of subjects: 81
Study 20584759 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral shoe
Number of subjects: 81
Study 20584759 — intervention group
Group type: COMPARATOR
Intervention: Highly pronated foot
Number of subjects: 81
Study 19953773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded with a two-step, total-etch adhesive (Single Bond 2)
Number of subjects: 70
Study 19953773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lined with a resin-modified GIC liner (Fuji Lining LC), then bonded with total-etch adhesive
Number of subjects: 70
Study 19953773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded with a two-step, self-etch adhesive (Clearfil SE Bond)
Number of subjects: 70
Study 19953773 — intervention group
Group type: EXPERIMENTAL
Intervention: Lined with the GIC liner, then bonded with self-etch adhesive
Number of subjects: 70
Study 16761834 — intervention group
Group type: EXPERIMENTAL
Intervention: Shannon entropy (ShEn)
Number of subjects: 0
Study 16761834 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate entropy (ApEn)
Number of subjects: 0
Study 16761834 — intervention group
Group type: EXPERIMENTAL
Intervention: Lempel‐Ziv complexity (LZC)
Number of subjects: 0
Study 16761834 — intervention group
Group type: EXPERIMENTAL
Intervention: Higuchi fractal dimension (HFD)
Number of subjects: 0
Study 16761834 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral entropy
Number of subjects: 0
Study 16761834 — intervention group
Group type: COMPARATOR
Intervention: Ramsay score (clinical depth of sedation score)
Number of subjects: 0
Study 15277410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart every hour (SC-1h)
Number of subjects: 45
Study 15277410 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin aspart every 2 hours (SC-2h)
Number of subjects: 45
Study 15277410 — intervention group
Group type: COMPARATOR
Intervention: Intravenous regular insulin (IV)
Number of subjects: 45
Study 11441410 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus gemcitabine
Number of subjects: 317
Study 11441410 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus cisplatin
Number of subjects: 317
Study 11441410 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus vinorelbine
Number of subjects: 317
Study 11441410 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan
Number of subjects: 317
Study 9205509 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 6 weeks
Number of subjects: 148
Study 9205509 — intervention group
Group type: COMPARATOR
Intervention: 250 mg terbinafine daily for 12 weeks
Number of subjects: 148
Study 9205509 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg terbinafine daily for 6 weeks (in patients with fingernail infection)
Number of subjects: 148
Study 7961582 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 83
Study 7961582 — intervention group
Group type: COMPARATOR
Intervention: Typical neuroleptics
Number of subjects: 83
Study 3944997 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable pressure transducers changed every two days
Number of subjects: 157
Study 3944997 — intervention group
Group type: COMPARATOR
Intervention: Disposable pressure transducers changed every four days
Number of subjects: 157
Study 3944997 — intervention group
Group type: COMPARATOR
Intervention: Disposable pressure transducers changed every eight days
Number of subjects: 157
Study 29380961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated self-monitoring service
Number of subjects: 12
Study 29380961 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 12
Study 26893403 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated instruction on how to collect a clean uncontaminated midstream urine sample
Number of subjects: 240
Study 26893403 — intervention group
Group type: COMPARATOR
Intervention: No illustrated instruction (control group)
Number of subjects: 240
Study 26893403 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated instruction
Number of subjects: 240
Study 25037054 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive distancing (CD)
Number of subjects: 0
Study 25037054 — intervention group
Group type: COMPARATOR
Intervention: Cognitive challenge task
Number of subjects: 0
Study 22854553 — intervention group
Group type: EXPERIMENTAL
Intervention: A-solution (oral gargling with blended essential oils diluted with distilled water)
Number of subjects: 66
Study 15951645 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale
Number of subjects: 168
Study 15951645 — intervention group
Group type: COMPARATOR
Intervention: 4-point verbal rating scale
Number of subjects: 168
Study 12029406 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP mask plus assisted coughing (Group A)
Number of subjects: 27
Study 12029406 — intervention group
Group type: COMPARATOR
Intervention: Assisted coughing alone (Group B)
Number of subjects: 27
Study 10634176 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ selected blood progenitor cells
Number of subjects: 0
Study 10634176 — intervention group
Group type: COMPARATOR
Intervention: Nonselected blood progenitor cells
Number of subjects: 0
Study 7554018 — intervention group
Group type: EXPERIMENTAL
Intervention: Children identified as night blind (mean serum vitamin A level 16.3 micrograms/dl; 95% CI, 13.9‐18.7)
Number of subjects: 105
Study 7554018 — intervention group
Group type: COMPARATOR
Intervention: Children identified as not night blind (mean serum vitamin A level 23.6 micrograms/dl; 95% CI, 21.3‐25.9)
Number of subjects: 105
Study 2309102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic training
Number of subjects: 67
Study 2309102 — intervention group
Group type: COMPARATOR
Intervention: Static training
Number of subjects: 67
Study 7250591 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.375 mg/day)
Number of subjects: 0
Study 7250591 — intervention group
Group type: COMPARATOR
Intervention: Beta-methyldigoxin (0.25 mg/day)
Number of subjects: 0
Study 29940089 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 1293
Study 29940089 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 1293
Study 27980008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg + Febuxostat 80 mg
Number of subjects: 32
Study 27980008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arhalofenate 600 mg + Febuxostat 80 mg
Number of subjects: 32
Study 27980008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg + Febuxostat 40 mg
Number of subjects: 32
Study 27980008 — intervention group
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Number of subjects: 32
Study 27980008 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat
Number of subjects: 32
Study 27980008 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Arhalofenate and Febuxostat
Number of subjects: 32
Study 26184655 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led BLS training
Number of subjects: 1087
Study 26184655 — intervention group
Group type: COMPARATOR
Intervention: Professional-led BLS training
Number of subjects: 1087
Study 24438566 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated osteogenic orthodontic group (AOO)
Number of subjects: 10
Study 24438566 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 20963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day for 7 days followed by 5 mg/kg/day for a maximum of 6 weeks
Number of subjects: 220
Study 20963840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 20963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 220
Study 20963840 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin in Ureaplasma subgroup
Number of subjects: 220
Study 20963840 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Ureaplasma subgroup
Number of subjects: 220
Study 18320254 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically modified potatoes (3 mg zeaxanthin)
Number of subjects: 3
Study 18320254 — intervention group
Group type: COMPARATOR
Intervention: Wild-type control potatoes (0.14 mg zeaxanthin)
Number of subjects: 3
Study 16233990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet (32 treatment sessions over 12 months)
Number of subjects: 197
Study 16233990 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (discarded 15 subjects who preferred this diet)
Number of subjects: 197
Study 12760986 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 93
Study 12760986 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 93
Study 12760986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 10712997 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT) for 3 months
Number of subjects: 23
Study 10712997 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 23
Study 10712997 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 23
Study 9198292 — intervention group
Group type: EXPERIMENTAL
Intervention: nizatidine (2 x 150 mg twice daily), amoxicillin (2 x 250 mg four times daily), clarithromycin (2 x 250 mg three times daily) for two weeks (niz-amox-clar group, N = 25)
Number of subjects: 75
Study 9198292 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole (20 mg twice daily), clarithromycin (2 x 250 mg three times daily) for two weeks (ome-clar group, N = 25)
Number of subjects: 75
Study 9198292 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (300 mg four times daily), amoxicillin (2 x 250 mg four times daily), metronidazole (250 mg four times daily) for two weeks (triple therapy group, N = 25)
Number of subjects: 75
Study 1545557 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous removal
Number of subjects: 50
Study 1545557 — intervention group
Group type: COMPARATOR
Intervention: Surgical removal
Number of subjects: 50
Study 4085468 — intervention group
Group type: EXPERIMENTAL
Intervention: Digby‐Leigh valve with inspiratory resistance of 7 cmH2O l‐1s and high expiratory resistance of 25 cmH2O l‐1s (DLS)
Number of subjects: 15
Study 4085468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 12 cmH2O l‐1s (IRS1)
Number of subjects: 15
Study 4085468 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory resistive load of 25 cmH2O l‐1s (IRS2)
Number of subjects: 15
Study 4085468 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance control system
Number of subjects: 15
Study 29997249 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mTOR inhibitor therapy (combination of BEZ235 and RAD001)
Number of subjects: 264
Study 26264446 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic breast cancer screening (clinical breast examination and referral for mammographic screening)
Number of subjects: 7436
Study 26264446 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no explicit instruction for breast screening or mammography referrals)
Number of subjects: 7436
Study 26264446 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic breast cancer screening
Number of subjects: 7436
Study 26264446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 7436
Study 24235073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency on-line haemodiafiltration (HDF)
Number of subjects: 42
Study 24235073 — intervention group
Group type: COMPARATOR
Intervention: High-flux haemodialysis (HD)
Number of subjects: 42
Study 22383266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bergamot essential oil inhalation
Number of subjects: 37
Study 22383266 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care (Control)
Number of subjects: 37
Study 20174583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmed K4b(2) portable metabolic analyzer
Number of subjects: 19
Study 20174583 — intervention group
Group type: COMPARATOR
Intervention: Medgraphics D‐Series stationary gas exchange system
Number of subjects: 19
Study 18525391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined endurance training (ET)/Resistance training (RT) for 12 weeks
Number of subjects: 38
Study 18525391 — intervention group
Group type: COMPARATOR
Intervention: Endurance training (ET) alone for 12 weeks
Number of subjects: 38
Study 18525391 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ET/RT and ET groups
Number of subjects: 38
Study 15877554 — intervention group
Group type: EXPERIMENTAL
Intervention: NITE-AD intervention (sleep hygiene education, daily walking, increased light exposure)
Number of subjects: 36
Study 15877554 — intervention group
Group type: EXPERIMENTAL
Intervention: NITE-AD intervention
Number of subjects: 36
Study 15877554 — intervention group
Group type: COMPARATOR
Intervention: Control (general dementia education and caregiver support)
Number of subjects: 36
Study 12700935 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia (MUA) with intra-articular normal saline injection
Number of subjects: 100
Study 12700935 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA) alone
Number of subjects: 100
Study 12700935 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA) with intra-articular methylprednisolone injection
Number of subjects: 100
Study 10472779 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate) at a daily total dose of 500 mg
Number of subjects: 90
Study 10472779 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment)
Number of subjects: 90
Study 10472779 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA (medroxyprogesterone acetate)
Number of subjects: 90
Study 8758107 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg, Isoniazid 400 mg, and Pyrazinamide 1.25 g daily for 3 months
Number of subjects: 382
Study 8758107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 1765317 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nalbuphine
Number of subjects: 137
Study 1765317 — intervention group
Group type: COMPARATOR
Intervention: 50 mg pethidine
Number of subjects: 137
Study 6751144 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20
Study 6751144 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular regime
Number of subjects: 20
Study 31145388 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal isometric fatiguing exercise
Number of subjects: 20
Study 31145388 — intervention group
Group type: COMPARATOR
Intervention: Submaximal isometric fatiguing exercise
Number of subjects: 20
Study 31145388 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal intermittent isometric contractions
Number of subjects: 20
Study 30450637 — intervention group
Group type: EXPERIMENTAL
Intervention: 3K3A-APC at 540 μg/kg
Number of subjects: 110
Study 30450637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 28320473 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP-SD Twins (5 home visits in a 3-month period)
Number of subjects: 100
Study 28320473 — intervention group
Group type: COMPARATOR
Intervention: Dummy intervention
Number of subjects: 100
Study 26477023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy and relaxation treatment (SHE treatment)
Number of subjects: 73
Study 26477023 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 73
Study 23639598 — intervention group
Group type: EXPERIMENTAL
Intervention: RM-131 (100 μg, subcutaneously)
Number of subjects: 10
Study 23639598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21062115 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) 100 U
Number of subjects: 29
Study 21062115 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 29
Study 21062115 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 29
Study 19116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Active corner inflammatory lesion (CIL) on MRI
Number of subjects: 29
Study 19116919 — intervention group
Group type: COMPARATOR
Intervention: No active inflammation on MRI
Number of subjects: 29
Study 19116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolved CIL after anti-TNF treatment
Number of subjects: 29
Study 19116919 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation on baseline MRI
Number of subjects: 29
Study 19116919 — intervention group
Group type: COMPARATOR
Intervention: No inflammation on baseline MRI
Number of subjects: 29
Study 17606024 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 17606024 — intervention group
Group type: COMPARATOR
Intervention: Current indications for CPAP
Number of subjects: 0
Study 15141043 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted surgery
Number of subjects: 872
Study 15141043 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 872
Study 11212971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg daily for 2 weeks, then 100 mg daily for 4 weeks
Number of subjects: 16
Study 11212971 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 30 mg daily for 2 weeks, then 60 mg daily for 4 weeks
Number of subjects: 16
Study 11189192 — intervention group
Group type: EXPERIMENTAL
Intervention: Taileqi troches
Number of subjects: 100
Study 11189192 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 100
Study 8086844 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop on medical ethics for family medicine preceptors
Number of subjects: 68
Study 8086844 — intervention group
Group type: COMPARATOR
Intervention: Control group of preceptors not invited to the workshop
Number of subjects: 68
Study 2584586 — intervention group
Group type: EXPERIMENTAL
Intervention: Spherical soft contact lenses
Number of subjects: 16
Study 4556011 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-chlorotestosterone acetate
Number of subjects: 0
Study 4556011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28888614 — intervention group
Group type: EXPERIMENTAL
Intervention: Curricular intervention group (IG)
Number of subjects: 181
Study 28888614 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 181
Study 26807967 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 62
Study 26807967 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time adherence monitoring
Number of subjects: 62
Study 26807967 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SMS reminders and real-time monitoring
Number of subjects: 62
Study 25011982 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD50F)
Number of subjects: 3
Study 25011982 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD90F)
Number of subjects: 3
Study 25011982 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide treatment (GD108F)
Number of subjects: 3
Study 25011982 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreated pigs)
Number of subjects: 3
Study 22236137 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 210 mg/2 weeks
Number of subjects: 404
Study 22236137 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 300 mg/2 weeks
Number of subjects: 404
Study 22236137 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine-LAI 405 mg/4 weeks
Number of subjects: 404